Gene · 6595
Papers3,459
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 3,459
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Long-lasting metabolic impairment in the failing heart: epigenetic memories at play. | Epigenetics | 2025 | 40492343 | PubTator, text mining | PubMed |
| Biophysical Approaches for Investigating the Dynamics and Cooperativity of Ternary Complexes in Targeted Protein Degradation. | J Med Chem | 2025 | 40472140 | PubTator, text mining | PubMed |
| GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy. | Res Sq | 2025 | 40470240 | PubTator, text mining | PubMed |
| Case Report: FAP+ fibroblasts and SPP1+ macrophages in SMARCA2-deficient while SMARCA4-preserved poorly differentiated lung adenocarcinoma: two case reports and multi-omics analysis. | Front Immunol | 2025 | 40453096 | PubTator, text mining | PubMed |
| Concurrent SMARCA4-deficient and poorly differentiated adenocarcinomas in separate lung lobes: a case report and literature review. | World J Surg Oncol | 2025 | 40405273 | PubTator, text mining | PubMed |
| Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models". | J Med Chem | 2025 | 40395158 | PubTator, text mining | PubMed |
| Molecular heterogeneity of small cell lung cancer and new therapeutic possibilities: a narrative review of the literature. | Transl Lung Cancer Res | 2025 | 40386726 | PubTator, text mining | PubMed |
| SMARCA4 deficiency: implications for non-small cell lung cancer and management strategies, with relevance to and distinctions from thoracic undifferentiated tumor. | Transl Lung Cancer Res | 2025 | 40386720 | PubTator, text mining | PubMed |
| Gfi1 controls the formation of effector-like CD8+ T cells during chronic infection and cancer. | Nat Commun | 2025 | 40374625 | PubTator, text mining | PubMed |
| Incomplete paralog compensation generates selective dependency on TRA2A in cancer. | PLoS Genet | 2025 | 40367120 | PubTator, text mining | PubMed |
| A Survey for Human Tissue-Level Determinants of CAV1 Regulation and Function. | Int J Mol Sci | 2025 | 40332409 | PubTator, text mining | PubMed |
| Cellular parameters shaping pathways of targeted protein degradation. | Commun Biol | 2025 | 40316744 | PubTator, text mining | PubMed |
| Clinicopathological characterization of Switch/Sucrose-non-fermentable (Swi/Snf) complex (ARID1A, SMARCA2, SMARCA4)-deficient endocervical adenocarcinoma. | Cancer Cell Int | 2025 | 40301885 | PubTator, text mining | PubMed |
Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors. | J Med Chem | 2025 | 40280558 | PubTator, text mining | PubMed |
| Artificial intelligence-driven genotype-epigenotype-phenotype approaches to resolve challenges in syndrome diagnostics. | EBioMedicine | 2025 | 40280028 | PubTator, text mining | PubMed |
| Chromatin remodeling and cancer: the critical influence of the SWI/SNF complex. | Epigenetics Chromatin | 2025 | 40269969 | PubTator, text mining | PubMed |
| A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies. | Clin Cancer Res | 2025 | 40238563 | PubTator, text mining | PubMed |
| 1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer. | ACS Med Chem Lett | 2025 | 40236548 | PubTator, text mining | PubMed |
| Ternary Complex Modeling, Induced Fit Docking and Molecular Dynamics Simulations as a Successful Approach for the Design of VHL-Mediated PROTACs Targeting the Kinase FLT3. | Arch Pharm (Weinheim) | 2025 | 40223615 | PubTator, text mining | PubMed |
| Whole-Genome Sequencing Reveals Individual and Cohort Level Insights into Chromosome 9p Syndromes. | medRxiv | 2025 | 40196253 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6595/papers?page=8